Author:
Handa Preha, ,Joshi Venkatesh M.,Sahoo Ashok K.,K Sainath,Matam Naganandeshwar,Kumar Nitin
Abstract
Liquisolid technique is an emerging technology of formulation development. In the present work, a modified-release formulation of gliclazide was developed by using the liquisolid technique. Gliclazide was dispersed in a nonvolatile solvents system of Tween 80 and propylene glycol, followed by adsorbing the liquid medication on carrier material MCC pH 102. Drug release rate controlling polymer HPMC was wet granulated with binder solution along with diluent. The two blends of API liquisolid and polymer mixture were blended uniformly with extra granular excipients to manufacture gliclazide modified release tablets 30 mg. Characterization of gliclazide liquisolid tablets was done using analytical techniques, i.e., FTIR and XRD. The optimization of the formulation was done by using mixture design where the amount of propylene glycol, Tween 80, DCP (anhydrous), HPMC K4M and HPMC K100 LVCR were considered to be the independent formulation variables. The dissolution and hardness were considered as dependent variables. The formulations were evaluated for dissolution, assay, hardness, thickness and other vital properties. The liquisolid formulation showed a zero-order release pattern and matched with the innovator (Diamicron MR 30 mg). The modified release tablets showed good stability at 40 °C / 75% RH for three months.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference13 articles.
1. 1. Kamble P. R., Shaikh K. S., and Chaudhari P. D.: Application of liquisolid technology for enhancing solubility and dissolution of rosuvastatin, Adv Pharm Bull. 2014 (4), 197-204.
2. 2. Tayel S. A., Soliman I. I., and Louis D.: Improvement of dissolution properties of Carbamazepine through application of the liquisolid tablet technique, Eur J Pharm Biopharm. 2008, 69(1), 342-347.
3. 3. Spireas S., Sadu S., Grover R.: In vitro release evaluation of hydrocortisone liquisolid tablets, J Pharm Sci. 1998, 87 (7), 867-72.
4. 4. Khaled K. A., Asiri Y. A., El-Sayed Y. M.: In vivo evaluation of hydrochlorothiazide liquisolid tablets in beagle dogs, Int J Pharm. 2001, 222 (1), 1-6.
5. 5. Khanfar M., Sheikh Salem M., Hawari R.: Formulation factors affecting the release of ezetimibe from different liquisolid compacts. Pharm. Dev. Technol. 2013, 18 (2), 417-27.